Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Tycho Peterson | Jefferies | 14 questions · 7% challenging |
| Mike Ryskin | Bank of America | 14 questions · 0% challenging |
| Dan Brennan | TD Cowen | 14 questions · 0% challenging |
| Scott Davis | Melius Research | 13 questions · 0% challenging |
| Vijay Kumar | Evercore ISI | 12 questions · 0% challenging |
| Jack Meehan | Operon Research | 10 questions · 0% challenging |
| Doug Schenkel | Wolfe Research | 10 questions · 20% challenging |
| Rachel Vatnsdal | JPMorgan | 6 questions · 0% challenging |
| Dan Leonard | RBC Capital Markets | 5 questions · 0% challenging |
| Casey Woodring | JPMorgan | 4 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| TD Cowen | 1 analyst | 14 questions · 0% challenging |
| Jefferies | 1 analyst | 14 questions · 7% challenging |
| Bank of America | 1 analyst | 14 questions · 0% challenging |
| Melius Research | 1 analyst | 13 questions · 0% challenging |
| Evercore ISI | 1 analyst | 12 questions · 0% challenging |
| Wolfe Research | 1 analyst | 10 questions · 20% challenging |
| JPMorgan | 2 analysts | 10 questions · 0% challenging |
| Operon Research | 1 analyst | 10 questions · 0% challenging |
Reporting soon: earnings call Wednesday, Oct 21
A pre-earnings brief is ready for DHR: the setup, what peers and partners said this season, and which analysts to watch.Reading it is a Tellvest Pro feature.
Danaher posted Q1 sales of $6.0 billion with core revenue up 0.5% (including a 2.5% respiratory headwind) and adjusted EPS of $2.06, up 9.5%. Full-year adjusted EPS guidance was raised to $8.35-8.55 while the Masimo acquisition advanced the acute care strategy. Bioprocessing equipment orders inflected positive, China recovery broadened across the portfolio, and operating margin expanded on DBS cost savings with free cash flow conversion at 105%.
Revenue Growth | Demand | Guidance Reliability | Capex Investment | M&A | Geographic Expansion | Trade Tariffs | Margin | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 6 | 4 | 3 | 1 | 2 | 1 | 1 | |
| 2025Q1 | 5 | 5 | 3 | 1 | 2 | 2 | 4 | 1 |
| 2025Q2 | 7 | 8 | 3 | 1 | 2 | 2 | 1 | |
| 2025Q3 | 7 | 5 | 2 | 3 | 1 | 3 | 1 | 1 |
| 2025Q4 | 8 | 9 | 5 | 2 | 2 | 1 | 3 | |
| 2026Q1 | 5 | 5 | 3 | 2 | 3 | 1 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6 | 5 | 7 | 7 | 8 | 5 |
| Demand | 4 | 5 | 8 | 5 | 9 | 5 |
| Guidance Reliability | 3 | 3 | 3 | 2 | 5 | 3 |
| Capex Investment | 1 | 1 | 1 | 3 | 2 | 2 |
| M&A | 2 | 2 | 1 | 2 | 3 | |
| Geographic Expansion | 1 | 2 | 2 | 3 | 1 | 1 |
| Trade Tariffs | 1 | 4 | 2 | 1 | ||
| Margin | 1 | 1 | 1 | 3 | 2 |
No 8-K events recorded for this window.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $6.54B | +2.1% | $1.49 | +2.8% | 59.5% | 26.7% | 16.6% | $1.50B |
| FY2025 Q1 | $5.74B | -0.9% | $1.32 | -9.0% | 61.2% | 22.2% | 16.6% | $1.05B |
| FY2025 Q2 | $5.94B | +3.4% | $0.77 | -36.9% | 66.6% | 20.1% | 9.3% | $1.09B |
| FY2025 Q3 | $6.05B | +4.4% | $1.27 | +13.4% | 58.2% | 19.1% | 15.0% | $1.37B |
| FY2025 Q4 | $6.84B | +4.6% | $1.68 | +12.8% | 58.0% | 22.0% | 17.5% | $1.75B |
| FY2026 Q1Selected | $5.95B | +3.7% | $1.45 | +9.8% | 60.3% | 22.6% | 17.3% | $1.08B |
| FY2026 Q2 | $6.26B | +5.5% | $1.23 | +59.7% | 57.6% | 18.0% | 13.9% | $1.26B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q1 2026Earnings call Apr 21, 2026
FY2026 Q1 in brief
Danaher posted Q1 sales of $6.0 billion with core revenue up 0.5% (including a 2.5% respiratory headwind) and adjusted EPS of $2.06, up 9.5%.
Newest quarter FY2026 Q2 is part of Pro · see what Pro adds →
GAAP revenue YoY +3.66% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
Sources. Tellvest earnings-call sentiment score for Danaher Corporation (DHR), FY2026 Q1: 7/10. Scores: Danaher Corporation’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: DHR daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
What DHR and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“Beckman Coulter Life Sciences announced a strategic partnership with Automata, combining its liquid handling genomic and cell analysis technologies with Automata's AI-ready automation platform.”
Danaher's Beckman Coulter Life Sciences partnered with Automata to combine its liquid-handling tech with Automata's AI-ready lab automation platform.
“including the pending acquisition of Masimo, where we believe there are significant opportunities to improve performance over time through DBS and our global scale.”
Danaher's pending acquisition of pulse-oximetry leader Masimo supports its acute-care diagnostics strategy alongside Radiometer.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
DHR Danaher Corporation | 7 | +3.7% | |
| A Agilent Technologies | 6 | +7.0% | |
| CRL Charles River Laboratories | 4 | +1.2% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| ILMN Illumina, Inc. | 8 | +4.8% | |
| IQV IQVIA | 7 | +8.4% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |